Transform Your New SB431542 Into A Complete Goldmine

6 mg) based on the maximum approved dose in the study location. All subjects enrolled were required to be on a stable metformin dose of at least 1,500 mg or greater with an HbA1c of 7%�C9.5%. Subjects were not eligible if they had an estimated glomerular selleck chemical filtration rate (eGFR) of less than 55 mL/min/1.73 m2 (or less than 60 mL/min/1.73 m2 based on the restrictions for metformin at the study center). Additionally, they were required to have a serum creatinine of less than 124 ��mol/L for men and less than 115 ��mol/L for women. Lastly, subjects with a history of more than one episode of severe hypoglycemia within 6 months prior to enrollment were not allowed to enter the trial.19 The primary endpoint of this trial was the change in HbA1c from baseline to week 52. Secondary efficacy endpoints included the following: percent change from baseline in body weight; proportion of patients achieving goal HbA1c; change in FPG, SBP, and diastolic blood pressure; and percent change in lipid parameters. The primary analysis was based on a modified intent-to-treat population which included all subjects who received at least one dose of study drug with the last observation carried forward. The trial was designed to prove that the addition of canagliflozin to metformin was non-inferior to the addition of a sulfonylurea. The pre-specified non-inferiority Megestrol Acetate margin was set at 0.3%. If non-inferiority was shown, superiority was determined if there was a less than 0% difference when compared to glimepiride.19 There were 1,450 subjects enrolled in the trial with equal distribution click here of subjects across the three groups. The mean age at the time of enrollment was 56 years, and the subjects were predominately white (67%) followed by Asian (19%), other (9%), and black or African American (5%). At baseline, subjects had been diagnosed with diabetes for approximately 6.6 years and had a mean HbA1c of 7.8% with a mean FPG of 9.2 mmol/L. The average body weight of subjects enrolled was 86.5 kg with a BMI of 31 kg/m2.19 In the efficacy analysis, both doses of canagliflozin were proven to be non-inferior to glimepiride, and the canagliflozin 300 mg dose reached the pre-specified superiority margin (Table 1). There was no significant difference in the percentage of patients achieving glycemic goal with approximately 60% achieving a goal HbA1c of